TSO3 — Investor Presentation (November 2017)
25 slides from TSO3's investor presentation, November 2017
Slide 1: To Create and Deliver the New Standard of Care in Sterile Reprocessing
To Create and Deliver the New Standard of Care in Sterile Reprocessing™ Corporate Presentation | November 2017 1
Slide 2: Important Cautions Regarding Forward Looking Statements and Other Disclosures
Important Cautions Regarding Forward Looking Statements and Other Disclosures The statements contained in this presentation and oral statements made by representatives of TSO3 Inc. (“Company”) relating to matters that are not historical facts are forward‐looking statements that involve certain risks
Slide 3: Vision and Purpose: A Sterile Device for Every Procedure
VISION. PURPOSE. To Create and Deliver The New Standard of Care In Sterile Reprocessing™ A Sterile Device for Every Procedure 3
Slide 4: Major Milestones Laying Foundation for Growth
Major Milestones Laying Foundation for Growth 1998 ‐ 2008 2009‐2014 2015 2016 2017 • Founded • Product redesign • Exclusive distribution • Shipped 110 • TTM Revenue of agreement with Getinge STERIZONE® VP4 $17.7M1 • HQ: Québec City, • Introduced ‐ $7.5M in cash + Sterilizers to Getinge Canada STERIZ
Slide 5: Global Market Opportunity
Global Market Opportunity United States • ~ 10,000 Hospitals and Ambulatory Surgery Centers1 • ~ 48 million annual procedures1 • ~ 15 million colonoscopies performed annually2 • > 500,000 endoscopic retrograde cholangiopancreatographies (ERCP Procedures) performed annually3 Canada • ~ 1,400 Hospital
Slide 6: STERIZONE VP4 Sterilizer
STERIZONE® VP4 Sterilizer Advantages • Single cycle – easy, error‐free cycle selection • Mixed load sterilization • Up to 75 Ib in a single load • Flexible Endoscope Clearance Proprietary Consumables (Razor/Razorblade Model) • 125‐280 Solution™ (H2O2) • STERIZONE® BI+ / Test Pack advanced process mo
Slide 7: Breakthrough Technologies: 138 Patents + 47 Patents Pending Worldwide
Breakthrough Technologies /// 138 Patents + 47 Patents Pending Worldwide 1. Insert Room Temperature Instruments Into a Warm Chamber 2. Create a Vacuum and Inject Small Amounts of Vapourized Heated Sterilant Over Time 3. Micro Condensation Forms on the Instruments Dynamic Sterilant Delivery SystemTM
Slide 8: Health Care Procedures
Health Care Procedures Surgical – OR Support • $6b+ Sterilization Existing Market1 • Growing Low Temperature Component Millions of Surgical and Diagnostic Procedures Each Year Diagnostic – GI • 50m+ Procedures/year2 • No sterilization for most 1) Market and Market, December 2016 2 )Becker’s GI & End
Slide 9: Aging Population – Driving Growth in MIS
Aging Population – Driving Growth in MIS Minimally Invasive Driving Growth in MI Surgeries and Endoscopies Surgery (MIS) Growth in U.S. Population Age Groups 65+1 90,000,000 • Effective 80,000,000 • Faster Recovery 70,000,000 • More profitable 60,000,000 50,000,000 40,000,000 Over 65 Years Old 30,00
Slide 10: A Better Solution for OR Support
A Better Solution for OR Support Old Technology TSO3 Next Generation Technology • 20+ year‐old core technology • Simple Single Cycle Operation • Single sterilant • Large Loads • Fixed delivery • Mixed Loads • Small loads • Lower Cost • Segregated loads • Lower Risk • Expensive Sterrad® NX Sterrad ®
Slide 11: Larger, Mixed Loads
Larger, Mixed Loads Competition VS STERIZONE® VP4 Sterilizer TSX:TOS 11
Slide 12: Health Care Procedures
Health Care Procedures Surgical – OR Support • $6b+ Sterilization Existing Market1 • Growing Low Temperature Component Millions of Surgical and Diagnostic Procedures Each Year Diagnostic – GI • 50m+ Procedures/year2 • No sterilization for most 1) Market and Market, December 2016 2 )Becker’s GI & End
Slide 13: Modernizing GI Endoscope Reprocessing
Modernizing GI Endoscope Reprocessing Old TSO3 STERIZONE® VP4 Sterilizer TSX:TOS 13
Slide 14: How Change Happens
How Change Happens Patient and Medical Technology Facility Demand Advancement • Patient Safety • STERIZONE® VP4 Sterilizer • Litigation = • Cost Reduction Market Change Regulatory Change • FDA Regulation Advancement • Industry Dialogue and Guidelines TSX:TOS 14
Slide 15: Not Sterile – Why?
Not Sterile – Why? Spaulding Classification TSX:TOS 15
Slide 16: A New Problem: Endoscopes and Superbugs
A New Problem: Endoscopes and Superbugs “Deaths from Drug‐Resistant Infections Set to Skyrocket” Deaths from antimicrobial resistant infections and other causes in 20501 Two million+ Americans suffer Carbapenem‐resistant CRE infections are linked to Inadequately‐cleaned endoscopes annually from anti
Slide 17: Industry First: FDA Clearance of TSO3 Endoscope Claims
Industry First: FDA Clearance of TSO3 Endoscope Claims CLEARED Video Colonoscope The only FDA cleared device validated to sterilize colonoscopes, gastroscopes and other flexible endoscopes up to 3.5m in length and with four or fewer channels. Video Gastroscope TSX:TOS TSX:TOS 17
Slide 18: Duodenoscopes – the point on the spear
Duodenoscopes – the point on the spear Duodenoscope Expanded Claims: FDA – Duodenoscopes • Already cleared in Canada and Europe • Launched US regulatory filings for duodenoscopes Market Launch and Awareness • Duodenoscopes now being terminally sterilized in Western Canada • Working with other US and
Slide 19: Public Awareness
Public Awareness Nation World Los Angeles Times HealthLeaders Media “FDA links ‘superbug‘ to key medical device.” “Jury orders Olympus to pay $6.6 million “Infection fears prompt Fujifilm but rejects claims its medical scopes are Medical Systems Duodenoscopes “LOS ANGELES — A ‘superbug‘ outbreak uns
Slide 20: Industry Call-to-Action
Industry Call‐to‐Action “Despite reprocessing in accordance with US “…Despite adherence to strict “We have to transition to sterilization. That guidelines, viable microbes and biologic debris guidelines…bacteria can at times remain on is the only way we’ll eliminate the persisted in clinically used
Slide 21: Shift is Happening
Shift is Happening • VA Officials Get • Dirty Endoscopes • Dirty Instruments Lead to • Nightmare Bacteria And Dirty Scopes ‐ • An Epidemic Is On the Rise That May • The Effectiveness of Sterilization For Probed For Using Raising Alarms for Investigation of Seattle Hospital Ignorance And Want in Medi
Slide 22: Commercialization
Commercialization Joacim Lindoff President of Surgical Workflows Getinge Group • Getinge Group ‐ Exclusive Global Distributor • Global sales and service; 3,000+ associates in 36 countries • Paid $7.5 million up‐front license fee • Minimum annual purchase commitments “The STERIZONE® VP4 Sterilizer un
Slide 23: Summary
Next Generation Technology Extensive Patent Portfolio Razor/Razorblade Business Model FDA‐cleared Device for Terminal Sterilization of Colonoscopes SUMMARY and other flexible endoscopes Global Distribution Partner Growing Sales Financially Sound TSX:TOS 23
Slide 24: Key Stats (TSX: TOS)
Key Stats (TSX: TOS) /// All Dollars in USD, Unless Noted Otherwise Stock Price (11/2/17) CAD$2.70 52 Week High‐Low CAD$3.73‐$2.05 Shares Outstanding (mrq) (no warrants) 92.8M Average Daily Volume (90 day) 183,766 Market Capitalization CAD$250M Institutional Holdings ~34% Total Revenue (mrq) $5.1M C
Slide 25: T Sh,
T Sh,